

Rabbit anti-Human MGMT/AGAT Monoclonal Antibody | anti-MGMT/AGAT antibody

MGMT/AGAT (EP337)

CATALOG # AAA59381	HOST Rabbit	REACTIVITY Human
------------------------------	-----------------------	----------------------------


PRODUCT SYNONYMS

MGMT/AGAT; Monoclonal Antibody; MGMT/AGAT (EP337); mgmt; agat; anti-mgmt; anti-agat; agt; anti-agt; anti-MGMT/AGAT antibody

PRODUCT SPECIFICATIONS

Host	Rabbit
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG
Clone Number	EP337
Form/Format	Paraffin, Frozen MGMT is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
Immunogen	A synthetic peptide corresponding to residues of the human MGMT protein.
Control	Breast, Cervix, Fallopian Tube, Prostate, Testis, Transitional Cell Carcinoma, Ductal Breast Carcinoma, Endometrial Carcinoma
Localization	Cytoplasmic, Nuclear
Preparation and Storage	Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)

IMAGES



IHC (Immunohistochemistry)

MGMT Antibody Immunohistochemistry on an FFPE Lung Adenocarcinoma Tissue

Antibody Type	Dilution	Volume/QT
Prediluted	Ready-To-Use	3.0 ml
Prediluted	Ready-To-Use	7.0 ml
Prediluted	Ready-To-Use	15.0 ml
Concentrated	1:50-1:200	0.1 ml
Concentrated	1:50-1:200	0.5 ml
Concentrated	1:50-1:200	1.0 ml
Control Slides		5

Dilution Info

ADDITIONAL INFORMATION

Related Product Information for anti-MGMT/AGAT antibody	MGMT is a house-keeping gene expressed in all tissues, and its promoter methylation and resulting down-regulation of the AGT protein varies among tumor types. The MGMT promoter contains many regulatory domains, and methylation can help decrease protein expression and therefore resistance to drugs, improving effectiveness of alkylating treatments. High MGMT antibody expression has been reported in Glioma, Myeloma, Melanoma, Colon and Pancreatic Cancers, where inhibition or down-regulation make alkylating drug treatments more effective. MGMT expression is lost in some cancer types such as Lymphomas, Non-Small Cell Lung Cancer, Astrocyte Tumors, Breast, and Prostate Cancer, where it may fail to prevent mutations. A study detected protein expression of MGMT by IHC and MGMT promoter methylation detected by methylation-specific polymerase chain reaction (MSP) were performed in a series of newly identified Glioblastomas and found that the MGMT status detected by either IHC or MSP was significantly correlated with the treatment response and survival of Glioblastoma patients. MGMT methylation is frequently observed in sporadic colorectal cancer and was recently correlated with the C>T allele at SNP rs16906252, within the transcriptional enhancer element of the promoter. MGMT methylation has also been associated with KRAS mutations, particularly G>A transitions. Another study address the association between sequence variants within the MGMT (O(6)-methylguanine-DNA methyltransferase) promoter-enhancer region and methylation of MGMT in premalignant lesions from smokers and lung adenocarcinomas, their biological effects on gene regulation, and targeting MGMT for therapy and found strong evidence that the A allele of a MGMT promoter-enhancer SNP is a key determinant for MGMT methylation in lung carcinogenesis. Moreover, TMZ treatment may benefit a subset of lung cancer patients methylated for MGMT.
---	---

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/monoclonal/mgmt-agat-antibody-clone-ep337-elisa/59381>